

Table SI. Topical calcineurin inhibitors included in the meta-analysis

Study	Intervention	Treatment duration (days)	Sample size in active treatment arm <i>n</i>	Sample size in control treatment arm <i>n</i>	Trial design
<i>Topical calcineurin inhibitors</i>					
Leung et al., 2009 (19)	Pimecrolimus 1% cream vs. vehicle	42	47	26	Parallel
Staab et al., 2005 (7)	Pimecrolimus 1% cream vs. vehicle	28	130	66	Parallel
Hoeger et al., 2009 (20)	Pimecrolimus 1% cream vs. vehicle	42	99	101	Parallel
Murrell et al., 2007 (21)	Pimecrolimus 1% cream vs. vehicle	42	101	99	Parallel
Aschoff et al., 2009 (22)	Pimecrolimus 1% cream vs. vehicle	21	20	20	Left/right
Langley et al., 2008 (8)	Pimecrolimus 1% cream vs. vehicle	42	267	136	Parallel
Kaufmann et al., 2006 (23)	Pimecrolimus 1% cream vs. vehicle	7	100	98	Parallel
Fowler et al., 2007 (24)	Pimecrolimus 1% cream vs. vehicle	8	86	88	Parallel
Baskan et al., 2007 (25)	Pimecrolimus 1% cream vs. vehicle	56	25	25	Left/right
Kaufmann et al., 2004 (26)	Pimecrolimus 1% cream vs. vehicle	28	130	66	Parallel
Ho et al., 2003 (9)	Pimecrolimus 1% cream vs. vehicle	42	123	63	Parallel
Schulz et al., 2007 (27)	Pimecrolimus 1% cream vs. vehicle	28	20	20	Parallel
Eichenfield et al., 2002 (10)	Pimecrolimus 1% cream vs. vehicle	42	267	136	Parallel
Meurer et al., 2004 (11)	Pimecrolimus 1% cream vs. vehicle	168	62	68	Parallel
Kapp et al., 2002 (8)	Pimecrolimus 1% cream vs. vehicle	365	204	47	Parallel
Luger et al., 2001 (32)	Pimecrolimus 1.0% cream vs. vehicle	21	45	43	Parallel
Rahman et al., 2008 (29)	Tacrolimus 0.3% ointment vs. vehicle	21	30	30	Parallel
Chapman et al., 2005 (30)	Tacrolimus 0.3% ointment vs. vehicle	42	310	308	Parallel
Boguniewicz et al., 1998 (33)	Tacrolimus 0.3% ointment vs. vehicle	22	44	44	Parallel
Schachner et al., 2005 (34)	Tacrolimus 0.03% ointment vs. vehicle	42	158	159	Parallel
Wollenberg et al., 2008 (31)	Tacrolimus 0.01% ointment vs. vehicle	365	116	108	Parallel
Reitamo et al., 2010 (12)	Tacrolimus 0.1% ointment vs. vehicle	365	80	73	Parallel
<i>Topical corticosteroids</i>					
Hebert et al., 2007 (35)	Desonide hydrogel 0.05% vs. vehicle	28	425	157	Parallel
Breneman et al., 2005 (36)	Clobetasol propionate lotion vs. vehicle	14	96	33	Parallel
Sugarman et al., 2009 (13)	Fluticasone propionate 0.05% cream vs. vehicle	28	62	59	Parallel
Lawlor et al., 1995 (38)	Prednicarbate 0.25% ointment vs. vehicle	28	24	27	Parallel
Gehring et al., 1996 (39)	1% Hydrocortisone vs. vehicle	7	32	31	Parallel
Peserico et al., 2008 (40)	Methylprednisolone aceponate 0.1% cream + emollient vs. emollient alone	112	112	109	Parallel
<i>Topical anti-histamines</i>					
Drake et al., 1994 (41)	Doxepin 5% cream vs. vehicle	7	132	138	Parallel
Lee et al., 2006 (42)	Doxepin 5% cream vs. vehicle	7	21	23	Parallel
Breneman et al., 1997 (65)	Doxepin 5% cream vs. vehicle	7	61	59	Parallel
Stainer et al., 2004 (43)	Sodium cromoglycate 4% lotion vs. vehicle	84	58	56	Parallel

Table SII. Other topical therapies included in the meta-analysis

Study	Intervention	Type of treatment	Treatment duration (days)	Sample size in active treatment arm <i>n</i>	Sample size in control treatment arm <i>n</i>	Trial design
Gueniche et al., 2008 (51)	V. filiformis cream 5% vs. vehicle	Non-pathogenic bacteria	30	37	38	Parallel
Lee et al., 2008 (16)	Rosmarinic acid 0.3% cream vs. vehicle	Anti-inflammatory	56	21	21	Left/right
Griffiths et al., 2002 (6)	Cipamfylline 0.15% cream vs. vehicle	Anti-inflammatory	14	54	54	Left/right
Patzelt-Wenzler et al., 2000 (44)	Kamillosan cream vs. vehicle	Anti-inflammatory	14	69	33	Left/right
Mayser et al., 2006 (45)	Ciclopiroxolamine 1% cream vs. vehicle	Anti-fungal	28	16	13	Parallel
Patrizi et al., 2008 (46)	MAS063DP vs. vehicle	Non-steroidal cream	43	20	20	Parallel
Abramovits et al., 2006 (47)	MAS063DP vs. vehicle	Non-steroidal cream	50	145	73	Parallel
Boguniewicz et al., 2008 (48)	MAS063DP vs. vehicle	Non-steroidal cream	43	72	70	Parallel
Giordano-Labadie et al., 2006 (49)	Exomega milk + cleansing bar vs. cleansing bar alone	Moisturizer	56	37	39	Parallel
Klövekorn et al., 2007 (50)	Ointment containing extracts from Mahonia aquifolium, Viola tricolor, and Centella asiatica (5 g/100 g ointment) vs. vehicle	Herbal	28	88	88	Left/right

Table SIII. Systemic therapies included in the meta-analysis

Study	Intervention	Treatment categorization	Treatment duration (days)	Sample size in active treatment arm <i>n</i>	Sample size in control treatment arm <i>n</i>	Trial design and duration
Senapati et al., 2008 (17)	Primrose oil 500 mg vs. placebo	Herbal	140	29	36	Parallel
Cheng et al., 2011 (57)	Xiao-Feng-San vs. placebo	Herbal	56	47	24	Parallel
Fölster-Holst et al., 2006 (58)	L. rhamnosus strain GG (LGG) vs. placebo	Probiotic	56	26	27	Parallel
Koch et al., 2008 (59)	Docosahexaenoic acid 5.4 g vs. placebo	Dietary supplementation	56	21	23	Parallel
Hannuksela et al., 1993 (56)	Cetirizine 40 mg vs. placebo	Anti-histamine	28	47	42	Parallel
Leung et al., 1990 (52)	Thymopentin vs. placebo	Immunosuppressant	42	48	52	Parallel
Stiller et al., 1994 (53)	Thymopentin vs. placebo	Immunosuppressant	84	20	19	Parallel
Friedmann et al., 2007 (54)	Montelukast vs. placebo	Immunosuppressant	56	30	30	Parallel
Oldhoff et al., 2005 (55)	Mepolizumab 750 mg vs. placebo	Immunosuppressant	14	20	23	Parallel
Hanifin et al., 1993 (66)	IFN- γ vs. placebo	Immunosuppressant	84	40	43	Parallel

Table SIV. Results summary of topical therapies

Study	RR	95% CI	% Weight
<i>Calcineurin Inhibitors^a</i>			
Leung et al., 2009 (19)	0.931	0.719–1.205	1.22
Staab et al., 2005 (7)	0.347	0.263–0.459	3.53
Hoeger et al., 2009 (20)	0.216	0.100–0.466	1.53
Murrell et al., 2007 (21)	0.475	0.346–0.653	3.11
Aschoff et al., 2009 (22)	0.417	0.180–0.964	0.56
Langley et al., 2008 (8)	0.637	0.532–0.763	5.70
Kaufmann et al., 2006 (23)	0.576	0.428–0.773	2.97
Fowler et al., 2007 (24)	0.651	0.508–0.834	3.05
Baskan et al., 2007 (25)	1.000	0.066–15.117	0.05
Kaufmann et al., 2004 (26)	0.570	0.467–0.696	3.53
Ho et al., 2003 (9)	0.427	0.307–0.594	2.60
Schulz et al., 2007 (27)	0.500	0.258–0.970	0.65
Eichenfield et al., 2002 (10)	0.670	0.562–0.799	5.70
Meurer et al., 2004 (11)	0.463	0.307–0.699	2.01
Kapp et al., 2002 (28)	0.602	0.387–0.935	1.37
Luger et al., 2001 (32)	0.600	0.405–0.888	1.17
Rahman et al., 2008 (29)	0.643	0.565–0.731	11.01
Chapman et al., 2005 (30)	1.611	1.295–2.006	2.52
Boguniewicz et al., 1998 (33)	0.664	0.495–0.889	1.72
Schachner et al., 2005 (34)	0.533	0.344–0.828	1.40
Wollenberg et al., 2008 (31)	0.566	0.463–0.690	5.64
Reitamo et al., 2010 (12)	1.628	1.270–2.085	1.81
<i>Sub-total M-H pooled RR</i>	<i>0.647</i>	<i>0.612–0.684</i>	<i>62.83</i>
<i>Topical Corticosteroids^b</i>			
Hebert et al., 2007 (35)	0.203	0.152–0.270	6.35
Breneman et al., 2005 (36)	0.486	0.373–0.633	2.02
Sugarman et al., 2009 (13)	0.714	0.460–1.107	1.34
Lawlor et al., 1995 (38)	0.216	0.099–0.474	1.14
Gehring et al., 1996 (39)	0.876	0.602–1.276	1.00
Peserico et al., 2008 (40)	3.147	2.301–4.304	1.42
<i>Sub-total M-H pooled RR</i>	<i>0.665</i>	<i>0.583–0.757</i>	<i>13.26</i>
<i>Anti-histamines^c</i>			
Drake et al., 1994 (41)	0.702	0.518–0.952	2.92
Lee et al., 2006 (42)	0.626	0.423–0.926	0.94
Breneman et al., 1997 (65)	0.903	0.743–1.097	2.19
Stainer et al., 2004 (43)	0.850	0.757–0.955	2.75
<i>Sub-total M-H pooled RR</i>	<i>0.790</i>	<i>0.701–0.892</i>	<i>8.80</i>
<i>Others^d</i>			
Lee et al., 2008 (16)	0.818	0.431–1.552	0.51
Griffiths et al., 2002 (6)	0.660	0.513–0.848	2.20
Patzelt-Wenzler et al., 2000 (44)	0.957	0.666–1.374	1.20
Mayser et al., 2006 (45)	1.083	0.504–2.327	0.31
Patrizi et al., 2008 (46)	0.400	0.230–0.696	0.93
Abramovits et al., 2006 (47)	0.261	0.181–0.379	3.23
Boguniewicz et al., 2008 (48)	0.259	0.167–0.404	2.84
Giordano-Labadie et al., 2006 (49)	0.843	0.522–1.362	0.91
Klövekorn et al., 2007 (50)	1.094	0.750–1.595	1.49
Gueniche et al., 2008 (51)	0.417	0.264–0.660	1.48
<i>Sub-total M-H pooled RR</i>	<i>0.551</i>	<i>0.484–0.628</i>	<i>15.11</i>
Overall M-H pooled RR^e	0.647	0.619–0.677	100.00

^az= 15.24. ^bz= 6.15. ^cz= 3.83. ^dz= 8.99. ^ez= 19.01. *p*<0.001 for all.

Table SV. Results summary of systemic therapies

Study	RR	95% CI	% Weight
<i>Immunosuppressants^a</i>			
Leung et al., 1990 (52)	0.813	0.650–1.016	16.09
Stiller et al., 1994 (53)	0.950	0.747–1.208	6.64
Friedmann et al., 2007 (54)	1.115	0.955–1.303	9.90
Oldhoff et al., 2005 (55)	0.703	0.448–1.103	6.38
Hanifin et al., 1993 (66)	0.847	0.640–1.121	12.12
<i>Sub-total M-H pooled RR</i>	<i>0.884</i>	<i>0.787–0.992</i>	<i>51.13</i>
<i>Anti-histamines^b</i>			
Hannuksela et al., 1993 (56)	0.709	0.497–1.011	11.67
<i>Sub-total M-H pooled RR</i>	<i>0.709</i>	<i>0.497–1.011</i>	<i>11.67</i>
<i>Others^c</i>			
Senapati et al., 2008 (17)	0.226	0.110–0.463	11.22
Cheng et al., 2011 (57)	0.599	0.462–0.777	11.60
Fölster-Holst et al., 2006 (58)	1.298	1.025–1.644	7.47
Koch et al., 2008 (59)	0.749	0.510–1.101	6.91
<i>Sub-total M-H pooled RR</i>	<i>0.655</i>	<i>0.547–0.784</i>	<i>37.20</i>
Overall M-H pooled RR ^d	0.778	0.706–0.857	100.00

Significance test(s) of RR=1

^az=2.09, *p*=0.037; ^bz=1.90, *p*=0.058; ^cz=4.60, *p*<0.001; ^dz=5.08, *p*<0.001.